New Delhi rejects American firm's plea to patent Hepatitis B drug- Pharmaceuticals-Healthcare / Biotech-News By Industry-News-The Economic Times

"The Delhi Patent Office has rejected American company Gilead Sciences’ plea to patent its Hepatitis B drug adefovir dipivoxil sold
under the brand name Hepsera. India’s largest drugmaker Ranbaxy had filed a pre-grant opposition against Gilead’s patent application saying that it is not a new drug and lacked inventions."